FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 醫渡科技有限公司 呈交日期： 2026年1月27日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | 事件 | 已發行股份（不包括庫存 ...

Group 1 - The company, Yidu Tech (02158.HK), announced a share buyback on January 26, spending HKD 758,000 to repurchase 126,000 shares [1]

Group 1 - The company, Yidu Tech (02158), announced a share buyback plan, committing to repurchase 126,400 shares at a total cost of HKD 758,100 [1] - The buyback price per share ranges from HKD 5.99 to HKD 6.00 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 醫渡科技有限公司 呈交日期： 2026年1月26日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件 ...

Core Insights - The founder and chairwoman of the company participated in the World Economic Forum's 56th Annual Meeting, engaging in high-level discussions on the intelligent transformation of the healthcare industry and the role of AI in addressing global health challenges [1][3][5]. Group 1: AI and Healthcare Resilience - The company emphasized the importance of AI and big data in enhancing public health system resilience and addressing new health challenges driven by climate change [1]. - AI healthcare enterprises can leverage technology to monitor climate-sensitive disease trends and innovate chronic disease management, thereby improving societal health resilience [1]. Group 2: AI in Health Security - The company highlighted the critical role of AI in infectious disease monitoring, drug development, and health management during discussions on reconstructing health security [3]. - The use of federated learning and privacy computing technologies is being implemented to enhance data security while improving model training efficiency across regions [3]. Group 3: China's AI Healthcare Development - The company discussed China's unique advantages in AI healthcare, including rich application scenarios, an improving data ecosystem, and strong policy support [5]. - The global value of China's experience lies not only in technological breakthroughs but also in systematic implementation capabilities and efficient localization models [5]. Group 4: Global Collaboration and Innovation - The company is actively building and expanding its collaboration network through bilateral meetings with key stakeholders, including government officials and industry leaders [7]. - A significant partnership was announced with Novartis for a cardiovascular disease prevention project, showcasing the company's commitment to AI-driven healthcare solutions [7]. Group 5: Contribution to Global AI Healthcare Ecosystem - The company's presence at the forum underscored the role of new-generation Chinese tech entrepreneurs in contributing to global wisdom and fostering cross-sector collaboration for a resilient future [8].

Core Insights - Novartis, in collaboration with the Brunei Ministry of Health and EVYD, is launching the CARDIO4Cities project aimed at cardiovascular disease prevention and control using data and AI tools [1][6][9] Group 1: Project Overview - The CARDIO4Cities project will utilize the BruHealth digital health platform to identify high-risk populations and implement targeted interventions to reduce cardiovascular disease risks in Brunei [1][6] - This initiative is part of a broader strategy to transform public health systems from reactive to proactive management, leveraging real-world data for precise health management [6][9] Group 2: Health Statistics and Challenges - Cardiovascular diseases account for over 70% of global deaths, with Brunei facing significant pressure on its public health system due to these diseases being the leading cause of mortality [6][8] - Common challenges in addressing these diseases globally include outdated data infrastructure, fragmented information, and weak monitoring systems, which hinder effective health interventions [6] Group 3: Technological Innovation - The project will employ AI-driven risk stratification for cardiovascular diseases, allowing for differentiated management strategies based on risk levels [6][7] - EVYD's AI capabilities will enhance drug development processes for pharmaceutical companies, improving clinical trial efficiency and cost control [7] Group 4: BruHealth Platform - The BruHealth platform, initially developed for tracking infectious diseases during the pandemic, has evolved into a comprehensive digital infrastructure covering over 85% of Brunei's population [8] - The platform integrates government oversight, healthcare provider tools, and personal health services, becoming a core component of Brunei's health management system [8] Group 5: Global Implications - The collaboration not only offers a new solution for cardiovascular disease management in Brunei but also serves as a model for addressing non-communicable diseases globally [9] - As the project progresses, it is expected to enhance public health services in Brunei and reduce the health and social burdens associated with cardiovascular diseases [9]

Core Insights - Novartis announced a significant collaboration at the 2026 World Economic Forum, focusing on a data-driven cardiovascular disease prevention project called CARDIO4Cities, in partnership with the Brunei Ministry of Health and EVYD, a subsidiary of Yidu Tech [1] - The project aims to leverage the BruHealth digital health platform to identify high-risk populations early and implement precise interventions, thereby reducing the risk of cardiovascular diseases and improving health management in Brunei [1] Group 1: Project Overview - The CARDIO4Cities project is designed to address the high burden of cardiovascular diseases, which are a leading cause of death globally, accounting for over 70% of deaths [8] - In Brunei, cardiovascular diseases are the primary cause of mortality, putting pressure on the public health system [8] - The project will utilize AI to categorize cardiovascular disease risk levels among the population and provide tailored management plans [8][9] Group 2: Technological and Systemic Innovations - The initiative represents a strategic national-level practice aimed at transforming public health systems from reactive to proactive, and from fragmented services to systematic governance [8] - The BruHealth platform, initially developed for tracking infectious diseases during the pandemic, has evolved into a comprehensive digital infrastructure covering over 85% of Brunei's population [10] - The collaboration will enhance data integration, analysis, and technical support for the project, with EVYD playing a key role [10] Group 3: Global Implications - The CARDIO4Cities project has been implemented in over 40 cities worldwide, with previous implementations showing potential to increase blood pressure control rates by 3 to 6 times and reduce stroke incidence by up to 13% [10] - This collaboration not only provides a new solution for cardiovascular disease prevention in Brunei but also serves as a reference model for global non-communicable disease management [11] - The project is expected to significantly improve public health services in Brunei and reduce the health and social burden of cardiovascular diseases [11]

Core Viewpoint - The long-term goal of medical AI is to build a comprehensive system covering the entire healthcare chain, with the industry still in its early development stage and vast future prospects [1][8]. Company Overview - Founded in 2014, the company has focused on "data intelligence and green healthcare," addressing supply chain and cost issues in the medical field, including aspects like physician time, pharmaceutical R&D, and insurance [2][11]. - The company has processed over 7 billion medical records, gaining valuable practical experience [2][11]. AI Applications and Ecosystem - The company has invested significantly in building an AI application ecosystem, including platforms for hospitals, diagnosis, and a "clinical doctor Copilot," aiming for an integrated architecture of "big data + big models + intelligent agents" [2][11]. - Approximately 70% of doctors in partnered hospitals use their created "intelligent agents" daily for various tasks, including data organization and patient management [3][11]. Drug Development and Insurance - The company assists pharmaceutical companies in new drug development through smart patient recruitment and workflow automation, focusing on AI Contract Research Organizations (CROs) [3][12]. - In the insurance sector, the company has participated in projects like Beijing Puhui Health Insurance and Shenzhen Huimin Insurance, aiming to reduce costs and expand coverage through AI [3][12]. Industry Development Stage - The medical AI industry is currently at a maturity level of "0.01" out of 100, primarily due to incomplete data in the physical world and the need for a deeper understanding of many diseases [4][13]. - The company anticipates exponential growth in the future, transitioning from linear accumulation to explosive growth as foundational work solidifies [4][13]. Global Expansion - The company is expanding its medical AI solutions to Southeast Asia and plans to enter the European market, emphasizing local partnerships due to the localized nature of healthcare [5][14]. - A health app launched in Brunei has reached nearly 90% population coverage, with daily user steps increasing from about 2,000 to 8,000 [5][14]. Industry Challenges and Value Creation - Each niche in the medical AI field presents challenges, requiring ongoing investment and refinement in areas like foundational models and medical knowledge graphs [6][15]. - The ability to create real value for clients is essential for sustainable development in the industry [7][16].

Core Viewpoint - The launch of the world's first "Hepatitis B Cure AI Assistant" by Yidu Technology in collaboration with Chongqing Medical University Second Affiliated Hospital aims to provide a comprehensive closed-loop service for Hepatitis B management, addressing issues such as fragmented information and inefficient clinical research recruitment [1][2]. Group 1: AI Assistant Features - The AI assistant is built on a medical domain-specific large model and offers a one-stop service covering screening, diagnosis, treatment, follow-up, and research [1]. - It operates on a smart management system that integrates clinical pathways and utilizes retrieval-augmented generation (RAG) technology to create a digital support system throughout the disease management process [1][2]. - The assistant acts as a "personal health manager," enabling continuous intelligent services for patients, including follow-ups, personalized education, health consultations, and appointment reminders [1]. Group 2: Clinical Collaboration and Data Integration - The AI assistant enhances clinical collaboration by covering the entire process from high-risk population screening to long-term follow-up and rehabilitation guidance, while also bridging the gap between research and clinical data [2]. - The collaboration between Yidu Technology and Chongqing Medical University has led to the establishment of a high-quality "Hepatitis B Specialty Database," which supports the AI assistant's capabilities [2]. - The assistant's effectiveness has been validated in clinical settings, demonstrating its ability to provide personalized risk assessments and decision support based on complex medical logic [2]. Group 3: Future Developments - The AI assistant is currently undergoing testing on both mobile and computer platforms, with plans for patients to access pre-consultation services and expert recommendations through a user-friendly interface [3]. - Yidu Technology plans to explore innovative services such as specialized large models and digital avatars for doctors, expanding the boundaries of intelligent management in the field of liver disease [3].

Core Viewpoint - The 56th Annual Meeting of the World Economic Forum will take place from January 19 to January 23 in Davos, Switzerland, focusing on the theme of "the spirit of dialogue" and gathering nearly 3,000 leaders from over 130 countries, including a record number of political leaders and top executives [1]. Group 1: Key Themes and Discussions - The session "Investing in Resilient Health" will explore sustainable health systems, emphasizing how intelligent technology can connect climate risks with health investment decisions to create more resilient and equitable health systems [2]. - The "Health Security Reimagined" session will highlight the integration of AI and big data in public health and drug development, advocating for a proactive approach to health security through global data sharing and collaboration [2]. - The discussion "China's Innovation, Deconstructed" will focus on China's unique path in healthcare technology innovation, examining how large-scale scenario-driven technology iterations and the resonance of policy, market, and technology can provide inclusive and efficient solutions for emerging markets [3]. Group 2: Engagement and Collaboration - During the annual meeting, the founder and chairwoman of Yidu Tech, Gong Rujing, will engage in multidimensional exchanges with global leaders from politics, business, and academia, participating in several national strategic dialogues [4]. - The insights shared by Gong Rujing, based on Chinese practices and a global perspective, are expected to contribute to the spirit of dialogue, fostering consensus and cooperation on key issues such as resilient health, security governance, and inclusive innovation [4].